Correspondence to: ‘Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’

Sheng‐Kai, Kevin; Wang, Li‐Tzu; Tsai, Shin‐Yi

doi:10.1136/annrheumdis-2020-218704

Cited by 12 publications

(9 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epidemiological data has revealed that pSS prevalence is approximately 1% of general population and female predominance (16:1) ( 2 ). Genetic inheritance and environmental factors are previously reported to enhance pSS pathogenesis; however, pSS etiology remains unclear, for which viral infection has been as well considered an external factor for it induces chronic inflammation ( 3 , 4 ). Viral particles translated by viral gene would act as autoantigens, which attract auto-antibodies to combine and trigger proliferation of B cells to cause autoimmune disease.…”

Section: Introductionmentioning

confidence: 99%

Risk of primary Sjogren’s Syndrome following human papillomavirus infections: a nationwide population-based cohort study

Chen

Dong

Chang³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

IntroductionViral infection is an exogeneous factor for primary Sjogren’s syndrome (pSS). This study investigated the association between human papillomavirus (HPV) infections and pSS through a nationwide population based cohort study.MethodsPatients with HPV infections between January, 1999 and December, 2013 were included. The incidence of new-onset pSS in patients with HPV infections and non-HPV controls were derived. The multiple Cox regression model derived the risk of pSS in patients with HPV infections. Subgroup analysis and sensitivity analysis were performed to validate the association.ResultsDuring a follow-up period of 12 years, the adjusted hazard ratio (aHR) of pSS in patients with HPV infections was significantly higher than that in non-HPV controls (aHR=1.64, 95% CI=1.47-1.83, P<0.001). The risk of pSS increased with age and the risk increased by 2.64-fold (95% CI= 2.37-2.93) for those older than 45 years. The significant association between HPV infections and the risk of pSS persisted in the sensitivity analysis restricted in HPV infections that lasted over 12 months (aHR=1.63, 95%CI=1.45-1.83, P<0.0001). Subgroup analyses revealed that both male (aHR=1.83, 95%CI=1.47-2.28, P<0.0001) and female (aHR=1.58, 95%CI=1.40-1.79, P<0.0001) patients with HPV infections and HPV-infected patients aged between 16 and 45 years (aHR=1.60, 95%CI=1.34-1.91, P<0.0001) and over 45 years (aHR=1.67, 95%CI=1.46-1.91, P<0.0001) were associated with a significantly greater risk of pSS.ConclusionPatients with HPV infections presented with a significantly higher risk of pSS, regardless of age and sex.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk of primary Sjogren’s Syndrome following human papillomavirus infections: a nationwide population-based cohort study

Chen

Dong

Chang³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunotherapy, which could be traced back to the late 19th century [69], has emerged as a promising treatment of cancer cells as well as infectious diseases [52,70]. For instance, cellular therapies from donor lymphocyte infusion are utilized to treat cancer relapse following allogeneic hematopoietic stem cell transplantation to bring about graft-vs-leukemia reaction [71][72][73], where antigen-experienced T cells would recognize pathogens such as cytomegalovirus or Epstein-Barr virus. Likewise, antigen-specific T cells acquired by cell expansion or genetically engineered pathogen-specific Tc clones have been applied to infectious diseases [74,75].…”

Section: Discussionmentioning

confidence: 99%

Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials

et al. 2021

Self Cite

View full text Add to dashboard Cite

Clinical trials evaluating the safety and antibody response of strategies to manipulate prophylactic and therapeutic immunity have been launched. We aim to evaluate strategies for augmentation of host immunity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. We searched clinical trials registered at the National Institutes of Health by 25 May 2021 and conducted analyses on inoculated populations, involved immunological processes, source of injected components, and trial phases. We then searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials for their corresponding reports published by 25 May 2021. A bivariate, random-effects meta-analysis was used to derive the pooled estimate of seroconversion and adverse events (AEs). A total of 929,359 participants were enrolled in 389 identified trials. The working mechanisms included heterologous immunity, active immunity, passive immunity, and immunotherapy, with 62.4% of the trials on vaccines. A total of 9072 healthy adults from 27 publications for 22 clinical trials on active immunity implementing vaccination were included for meta-analyses. The pooled odds ratios (ORs) of seroconversion were 13.94, 84.86, 106.03, and 451.04 (all p < 0.01) for vaccines based on protein, RNA, viral vector, and inactivated virus, compared with that of respective placebo/control treatment or pre-vaccination sera. The pooled ORs for safety, as defined by the inverse of systemic adverse events (AEs) were 0.53 (95% CI = 0.27–1.05; p = 0.07), 0.35 (95% CI = 0.16–0.75; p = 0.007), 0.32 (95% CI = 0.19–0.55; p < 0.0001), and 1.00 (95% CI = 0.73–1.36; p = 0.98) for vaccines based on protein, RNA, viral vector, and inactivated virus, compared with that of placebo/control treatment. A paradigm shift from all four immune-augmentative interventions to active immunity implementing vaccination was observed through clinical trials. The efficacy of immune responses to neutralize SARS-CoV-2 for these vaccines was promising, although systemic AEs were still evident for RNA-based and viral vector-based vaccines.

show abstract

“…The authors declare no conflicts of interest. Kevin Sheng-Kai Ma 1,2 Chien-Te Liu 3 Wei-Chiao Kao 3 Yung-Heng Lee…”

Section: Co N Fli C T S O F I Nte R E S Tmentioning

confidence: 99%

Long‐term safety and efficacy of methotrexate in patients with palindromic rheumatism

et al. 2022

View full text Add to dashboard Cite

Correspondence to: ‘Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’

Abstract: Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Cited by 12 publications

References 8 publications

Risk of primary Sjogren’s Syndrome following human papillomavirus infections: a nationwide population-based cohort study

Risk of primary Sjogren’s Syndrome following human papillomavirus infections: a nationwide population-based cohort study

Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials

Long‐term safety and efficacy of methotrexate in patients with palindromic rheumatism

Contact Info

Product

Resources

About